secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001558370-24-013889
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dogwood Therapeutics regains Nasdaq compliance; phase 2a Long-COVID data expected mid-Nov
--------------------------------------------------------------------------------

- Regained Nasdaq minimum bid price compliance; closing bid price >= $1.00 for 10 consecutive trading days.
- Top-line results from phase 2a study of IMC-2 for Long-COVID expected mid-November 2024.
- Integration of Pharmagesic (Holdings) Inc. acquisition (closed early Oct 2024) ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837024013889/0001558370-24-013889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837024013889/viri-20241029x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-013889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer